... failure with reduced ejection fraction (HFrEF) and chronic kidney disease (CKD); however, the risk of hyperkalemia (HK) is high. Methods: The DIAMOND trial (NCT03888066) assessed the ability of patiromer to control serum potassium (sK + ) in patients with HFrEF with/without CKD. Prior to randomization...

...Jaejin An; Hui Zhou; Liang Ni; Teresa N Harrision; Rong Wei; Abiy Agiro; Yasmin Ghanshyam Brahmbhatt; Yemmie Oluwatosin; Craig G. Schilling; John J. Sim Introduction: Discontinuation of renin-angiotensin-aldosterone system inhibitor (RAASi) is common after hyperkalemia. We evaluated the risk...

...Simon D. Roger; Bruce S. Spinowitz; Edgar V. Lerma; Bhupinder Singh; David K. Packham; Ayman Al-Shurbaji; Mikhail Kosiborod Background: Sodium zirconium cyclosilicate (SZC; formerly ZS-9) is a selective potassium (K + ) binder for treatment of hyperkalemia. An open-label extension (OLE...

... excluded patients with reduced kidney function due to risk of hyperkalemia. AMBER ( ClinicalTrials.gov identifier NCT03071263) will evaluate if the potassium-binding polymer patiromer used concomitantly with spironolactone in patients with RHTN and CKD prevents hyperkalemia and allows more persistent...

.../L POST ( p < 0.0001). sKmax increased from 5.3 ± 0.5 mmol/L PRE to 6.2 ± 0.6 mmol/L POST ( p < 0.0001). The percentage of pts with normal sK concentrations decreased from 82% PRE to 29% POST ( p < 0.0001). Mild hyperkalemia increased from 18 to 52% ( p < 0.001); in 31% of the patients...

...Pablo E. Pergola; David M. Spiegel; Suzette Warren; Jinwei Yuan; Matthew R. Weir Background: Patiromer is a sodium-free, nonabsorbed, potassium binder approved for treatment of hyperkalemia. This open-label study compares the efficacy and safety of patiromer administered without food versus...

... mEq/L. Diuretics and renin-angiotensin-aldosterone system inhibitors were related to hypokalemia and hyperkalemia respectively. Conclusion: Mortality risk progressively increased with dyskalemia and was differentially greater in those with HF, CKD, or DM. [email protected] 8 06 2017 6...

... with hyperkalemia in patients with reduced renal function even after the initiation of hemodialysis. Whether such medications may cause a similar effect in peritoneal dialysis patients is not well established. So, the aim of our study was to analyze the impact of renin-angiotensin-aldosterone inhibitors...

...David A. Bushinsky; Patrick Rossignol; David M. Spiegel; Wade W. Benton; Jinwei Yuan; Geoffrey A. Block; Christopher S. Wilcox; Rajiv Agarwal Background: Persistent hyperkalemia (serum potassium (K) ≥5.5 mEq/l) is a common condition in hemodialysis (HD) patients, is associated with increased...

...Akeem A. Yusuf; Yan Hu; Bhupinder Singh; José A. Menoyo; James B. Wetmore Background: Hyperkalemia is common in patients receiving maintenance hemodialysis. However, few studies have examined the association between serum potassium level and mortality. Methods: This study used annual cohorts...

...Charalampos Loutradis; Panagiota Tolika; Alexandra Skodra; Afroditi Avdelidou; Pantelis A. Sarafidis Background: Hyperkalemia is a potentially life-threatening disorder, usually complicating chronic kidney disease (CKD). Factors superimposed to reduced renal function are further elevating...

... was not associated with an increased risk of adverse events such as worsening anemia or hyperkalemia. Likewise, the correction of Hb with darbepoetin was not associated with any increase in thrombotic events. Conclusions: This study provides insight into the safety of RAS inhibition and Hb correction...

...Pravin C. Singhal; Lionel Desroches; Joseph Mattana; Mirel Abramovici; John D. Wagner; John K. Maesaka Hyperkalemia is a commonly encountered problem in dialysis patients with end-stage renal disease. In this study we evaluated the effect of mineralocorticoid therapy (MCT; fludrocortisone 0.1-0.3...

...Gregory A. Kozeny; Morrison Hurley; Leonard L. Vertuno; Vinod K. Bansal; Patrick Zeller; Jessie E. Hano An 8-week-old infant with hypertension, hyperkalemia, and hyperchloremic acidosis, presumably due to chloride shunt type of distal renal tubular acidosis, is described. The patient’s renin...

... dialysis (16 nondiabetics, 10 diabetics). The following potassium concentration frequencies were found: prehemodialysis, nondiabetics: normal 51.3%, severe hyperkalemia ( > 6.0 mmol/l) 10%, severe hypokalemia ( < 3.0 mmol/l) 0.3%; diabetics: normal 57.8%, severe hyperkalemia 8.7%, severe hypokalemia...

... by a semiquantitative index, the transtubular K concentration gradient (TTKG). TTKG values less than 6.0, consistent with less than maximal renal K secretion, were found in 28 of 29 patients despite the presence of hyperkalemia and/or stimuli for renin and aldosterone release. Plasma aldosterone levels on admission...

... to in the content or advertisements. Aldosterone Heparin Urinary electrolytes Potassium Hyperkalemia Adrenal insufficiency Diuretics Clinical Studies A m . J. Nephrol. 6: 165-168 (1986) © 1986 S. Karger AG. Basel 0250-8095/86/0063-0165S2.75/0 Suppression of Aldosterone Production by Low-Dose Heparin1...

...Gregory A. Kozeny; Morrison Hurley; Raoul Fresco; Leonard L. Vertuno; Vinod K. Bansal; Jessie E. Hano Hyperkalemia has been noted to occur spontaneously in patients with long-standing systemic lupus erythematosus who did not have advanced renal insufficiency. The patients previously described all...

...David D. Bercovitch; Michael Davidman; Michael Lichter Six patients with varying degrees of renal insufficiency developed severe hyperkalemia following hepatic necrosis. The hyperkalemia was seen prior to or concomitant with marked elevations in hepatic enzymes. The basis of the liver disease...

... with chronic renal failure are still responsive to maximal stimulation with aldosterone, in spite of their basically elevated fractional electrolyte output. These findings suggest that, with some exceptions, the hyperkalemia in patients with chronic renal failure is in part due to relative hypoaldosteronism...